Aligos therapeutics announces first subject dosed in the phase 2 b-supreme study of alg-000184 in subjects with chronic hbv infection

South san francisco, calif., aug. 13, 2025 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the phase 2 b-supreme study of its investigational compound alg-000184 has been initiated in subjects with chronic hepatitis b virus (hbv) infection.
ALGS Ratings Summary
ALGS Quant Ranking